

1

2

3

4 *Factors associated with viral Load re-suppression after enhanced adherence counseling among*  
5 *recipients of care with an Initial high viral load result in RISE-supported facilities in five States in*  
6 *Nigeria*

7 Gbenga Benjamin Obasa<sup>1\*</sup>, Mukhtar Ijaiya<sup>1¶</sup>, Ejike Okwor<sup>1&</sup>, Babafemi Dare<sup>1&</sup>, Franklin Emerenini<sup>2\*</sup>,  
8 Prince Anyanwu<sup>2&</sup>, Adewale Akinjeji<sup>2&</sup>, Kate Brickson<sup>3¶</sup>, Jennifer Zech<sup>4¶</sup>, Yemisi Ogundare<sup>1&</sup>, Emmanuel  
9 Atuma<sup>1&</sup>, Molly Strachan<sup>3¶</sup>, Ruby Fayorsey<sup>4¶</sup>, Kelly Curran<sup>3¶</sup>.

10

11

12

13 <sup>1</sup>Jhpiego, Nigeria

14 <sup>2</sup>ICAP Global Health, Nigeria

15 <sup>3</sup>Jhpiego, Baltimore

16 <sup>4</sup>ICAP Global Health, New York

17

18

19

20 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

21

22

23

24

25

26

27

28

29

30

31

32

33 \* Corresponding author

34 E-mail: [gbo2105@cumc.columbia.edu](mailto:gbo2105@cumc.columbia.edu) (GBO)

35 E-mail: [fe2204@cumc.columbia.edu](mailto:fe2204@cumc.columbia.edu) (FE)

36

37

38 ¶ These authors contributed equally to this work.

39 & These authors also contributed equally to this work.

40

41

## 42 Abstract

43 This study explores factors influencing viral re-suppression among 1,607 recipients of HIV care in  
44 Nigeria who completed Enhanced Adherence Counseling (EAC) between July 2021 and June 2022. The  
45 analysis, part of the Reaching Impact, Saturation, and Epidemic Control (RISE) project, utilized routine  
46 program data from 132 health facilities. Results showed a 91% re-suppression rate post-EAC, with age  
47 and ART regimen type identified as significant factors. Adolescents (10-19 years) had a higher  
48 likelihood of re-suppression, while ROC on second-line regimens exhibited lower resuppression rates.  
49 These findings inform programmatic decisions to enhance HIV treatment outcomes in Nigeria.

## 50 Background

51 The World Health Organization (WHO) recommends monitoring Viral load (VL) outcomes as the gold  
52 standard to measure the effectiveness of antiretroviral therapy (ART) for recipients of HIV care (ROC)  
53 [1,2]. In 2021, WHO revised its HIV treatment monitoring algorithm to assist ROC in reaching viral  
54 suppression and maintaining an undetectable VL with three categories of VL level: unsuppressed  
55 ( $\geq 1000$  copies/mL), suppressed (detected but  $< 1000$  copies/mL) and undetectable (VL not detected  
56 by test used)[3]. VL is considered unsuppressed when  $\geq 1000$  copies/ml for ROC undergoing treatment  
57 for more than six months. WHO recommends VL testing for ROCs on treatment for more than six  
58 months and then routinely every 12 months [1,4]. However, there are reports of low VL suppression  
59 rates among ROC living in low- and middle-income countries [5,6]. Poor adherence to HIV treatment is  
60 the most common reason for viral non-suppression and can potentially increase the risk of drug  
61 resistance, HIV treatment failure, and onward HIV transmission [7,8].

62

63 The WHO recommends Enhanced Adherence Counseling (EAC) for ROC with unsuppressed VL ( $\geq 1000$   
64 copies/ml) after six months of ART [2]. The EAC sessions lasting between 3–6 months are designed to  
65 improve adherence, identify possible barriers to treatment, and resolve treatment difficulties [5].  
66 Studies have shown that informing ROC about the risks of an unsuppressed VL result can improve  
67 treatment adherence [9]. This will reduce the chances of developing resistance mutations, treatment  
68 failure, or disease progression to advanced HIV disease [10]. The combination of EAC with routine VL  
69 has improved outcomes among people on ART [10–12]. A first-line treatment failure is established  
70 when VL suppression is not attained after EAC sessions. Subsequently, switching to second-line  
71 treatment is considered as different ART classes are associated with varying adherence thresholds  
72 needed to achieve viral suppression and avoid resistance mutations [13].

73

74 Nigeria has the second largest HIV epidemic in the world, with a total of 1.9 million (1.4%) persons (15-  
75 49 living with HIV as reported by the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) [14–16]. In  
76 2020, there were around 1.8 million HIV/AIDSs ROC, and about 67% of all people with HIV knew their  
77 status, but only 62% were on HIV treatment, of which 44% were estimated to be virally suppressed  
78 [16]. This VL suppression is sub-optimal compared to the UNAIDS third 95 target [15,16]. Studies have  
79 suggested several factors associated with VL non-suppression, such as poor medication adherence,  
80 suboptimal drug selection, and drug resistance [3,5,9]. Therefore, the need to assess the effectiveness  
81 of EAC in routine program implementation and determine factors associated with poor VL suppression  
82 is essential.

83

84 This analysis was conducted as part of the Reaching Impact, Saturation, and Epidemic Control (RISE)  
85 project, a five-year global project funded by the US President's Emergency Plan for AIDS Relief (PEPFAR)  
86 through the US Agency for International Development (USAID). We analyzed factors associated with  
87 viral re-suppression for ROC who enrolled and completed all EAC sessions between July 2021 and June

88 2022. We analyzed the demographic and clinical characteristics of ROC with unsuppressed VL ( $\geq 1000$   
89 copies/ml) who had completed EAC. This analysis will inform ongoing programmatic and clinical  
90 decision-making and improve health outcomes for ROC in Nigeria.

## 91 Methodology

### 92 Study design

93 A descriptive study using routinely collected service delivery data of ROC on ART in 132 RISE-  
94 supported health facilities from July 2021 to June 2022.

### 95 Program Setting and Description

96 The RISE project has been implemented in 132 facilities across 56 local government areas within five  
97 states in Nigeria, beginning in 2019: Adamawa, Akwa Ibom, Cross River, Niger, and Taraba. According  
98 to NAHS data, Akwa Ibom and Rivers have the highest number of HIV/AIDS ROC in Nigeria [15,17]. Akwa  
99 Ibom and Cross River states are located in the country's South-South region and have a prevalence rate  
100 of 4.8% and 1.8%, respectively [15]. In the northeast, Adamawa and Taraba have HIV prevalence rates  
101 of 2.6 and 1.1 %, respectively, while Niger in the north-central zone has a prevalence of 0.9% [15].

102

103 RISE provides EAC for virally unsuppressed ROC enrolled in ART services at supported facilities in  
104 alignment with WHO guidelines. EAC is also offered to ROC who receive drugs outside the facility at the  
105 community level. Children and adolescents ( $<15$  years) with an unsuppressed VL are also enrolled in  
106 the EAC program, with their caregivers attending the EAC sessions to assist with treatment adherence  
107 and VL suppression. According to WHO and Nigerian national guidelines, ROC with high VL results  
108 requires a repeat test after at least three EAC sessions. Recipients of care with VL results  $\geq 1000$   
109 copies/ml are enrolled into the EAC and closely monitored frequently with a minimum of 10 contacts

110 monthly for at least three months, which can be extended to a maximum of 6 months to assess  
111 adherence level, after which a VL test is carried out post-EAC. The EAC session is designed to help ROC  
112 identify the barriers they face in taking their treatment and formulate an adherence plan. Counselors  
113 help ROC identify their goals and provide emotional support to help them reach them. After completion  
114 of the EAC sessions, if the VL result is <1000 copies/ml post-EAC, the ROC remains on the same ART  
115 regimen. If the VL result is  $\geq 1000$  copies/ml after completion of the EAC sessions, the ROC is switched  
116 to a second-line ART regimen.

## 117 Program data

118 De-identified client-level data from the Lafiya Management Information System (LAMIS), a web-based  
119 electronic medical system, was used to identify HIV ROC on ART with VL  $\geq 1000$  copies per ml. Client  
120 information included in the data set were sex, date of birth, ART start date, days of ART refill, last drug  
121 pickup date, ART regimen type, date of VL testing, WHO clinical staging at last visit, tuberculosis (TB)  
122 status at last visit, date of commencement of EAC, EAC enrollment, date of last EAC Session and repeat  
123 VL result after completion of EAC. Data cleaning was carried out, for instance, by converting the birth  
124 date to age and then breaking it down into age-group categories. The variable "duration on ARTV" was  
125 derived from the difference between the start date of ART and the date of last drug pickup. Our  
126 outcome variable (VL result post-EAC) was then encoded as a binary classification, which indicated  
127 whether the patient was unsuppressed (VL  $\geq 1000$  copies/ml) or resuppressed (VL detected < 1000  
128 copies/ml).

129

## 130 Study population

131 The analysis was conducted using data collected as part of the routine implementation of the RISE  
132 project in Nigeria. Data were collected from 132 health facilities in five states: Adamawa, Akwa Ibom,  
133 Cross River, Taraba, and Niger.

### 134 ***Inclusion criteria***

135 All ROC enrolled in HIV care through the RISE project who have received ART for at least six months  
136 have VL results  $\geq 1000$  copies/ml and who started and completed EAC sessions (at least three sessions)  
137 between July 2021 and June 2022.

### 138 ***Exclusion criteria***

139 All ROC with no VL result, VL sample collection date, or ROC whose VL result was greater than one year  
140 were excluded. Also, ROC with data outside the selected period with no record of EAC session and  
141 documented post-EAC VL results were excluded.

### 142 **Data analysis**

143 Data were analyzed using SAS On-Demand version 9.04. The primary outcome of the analysis was VL  
144 suppression ( $< 1000$  copies/ml) after the completed EAC session. The analysis variables were sex, age,  
145 enrollment settings, clinical staging, TB co-infection, ARV regimen line, and duration on ART. Descriptive  
146 analyses were carried out to show demographic and clinical characteristics of ROC with unsuppressed  
147 VL ( $\geq 1000$  copies/ml), suppressed but detectable ( $\geq 50$  to  $< 1000$  copies/ml), and undetectable VL  
148 ( $< 50$  copies/ml). In addition, Pearson's Chi-Square was used to compare demographics, clinical  
149 characteristics, and VL re-suppression with a p-value of 0.05. Also, the Log binomial regression model  
150 was used to report crude and adjusted risk ratios with 95% Confidence Intervals (95% CI) to determine  
151 the association between clinical characteristics and VL re-suppression ( $< 1000$  copies/ml) on repeat  
152 testing, post-EAC.

### 153 **Ethical Statement**

154 This retrospective analysis was conducted with a firm commitment to ethical principles and guidelines.  
155 The medical records were accessed for research purposes on 26th, October 2022. It is crucial to  
156 highlight that rigorous de-identification measures were implemented, ensuring the privacy and

157 confidentiality of individual participants throughout the study. The research team did not have access  
158 to information that could identify individual participants during any phase of the research, and all data  
159 were anonymized before analysis.

160 The de-identification process involved the removal of any personally identifiable information and  
161 careful management of indirect identifiers that could potentially lead to participant identification. After  
162 completing the data analysis, archived samples, and records were securely stored.

## 163 Ethical Approval

164 The study received ethical approval from Johns Hopkins School of Public Health Institutional Review  
165 Board IRB#24824 "Secondary Data Analysis of HIV Prevention, Care and Treatment Service Delivery  
166 Programs in Africa, which explicitly reviewed and approved the de-identification procedures to  
167 safeguard participant confidentiality.

## 168 Results

169 A total of 127,198 ROC were on ART at RISE-supported Health Facilities, and 1607 (1.3%) completed  
170 EAC between July 2021 and June 2022 and had post-EAC VL results (Table 1). Among these participants,  
171 1,054 (66%) were female. The majority, 1,410 (88%), were enrolled in facility settings, and 1,506 (88%)  
172 were on a first-line ART regimen at their last visit. Most individuals (95%) were classified as WHO clinical-  
173 stage 1 at baseline, and 1,557 (97%) were free from TB co-infection. ROC aged 40 and above accounted  
174 for 37% (589), while children < 10 years accounted for 7% (114) of ROC included in this analysis.  
175 Approximately 22% (361) of the ROC included in this analysis had been on ART for two years or less.  
176 The median time taken to complete all recommended EAC sessions was 12 weeks. Over 90% of  
177 participants completed all recommended EAC sessions within three months. Following the completion  
178 of EAC sessions, the median time for collection of a repeat VL test was 8 weeks (Table 1). About 32% of  
179 the participants had a post-EAC VL test done after 8 weeks.



180

181 After the completion of EAC, a total of 1,454 individuals (91%) achieved a suppressed VL (<1000  
182 copies/ml) (Table 2). Among them, 336 (23%) had VL  $\geq$ 50 - < 1000 copies/ml, and 1,118 (76%) had an  
183 undetectable VL. Females comprised 66% of those who achieved VL re-suppression after EAC. The age  
184 group of 40 years and above had the highest proportion of individuals with re-suppressed VL, totaling  
185 542 (37%), compared to other age groups. In facility settings, 87% of ROC achieved VL re-suppression,  
186 totaling 1,267 individuals, while in community settings, 13% achieved re-suppression, comprising 187  
187 individuals. The majority of individuals with WHO clinical-stage 1 (91%) attained VL re-suppression after  
188 EAC. Additionally, 91% of ROC without TB co-infection achieved suppressed VL after EAC ( $p < 0.001$ ).  
189 Furthermore, 1,408 (93%) ROC on the first-line ART regimen achieved VL re-suppression, compared to  
190 ROC on second-line ART 46 (45%) ( $p < 0.001$ ). ROC on treatment for more than 3-5 years had a higher  
191 proportion of VL re-suppression than those on other durations of antiretroviral therapy ( $p < 0.031$ ). Table  
192 2 further details ROC characteristics and VL re-suppression in the RISE program.

193

194 **Table 1. Demographic and clinical characteristics of Recipients of Care (ROC) with unsuppressed VL**  
195 **(>1000 copies/ml of blood) who completed Enhanced Adherence Counselling (EAC).**

196

Characteristics	N	(%)
<b>Total</b>	<b>1607</b>	
<b>Gender</b>		
Female	1054	65.59
Male	553	34.41
<b>Age group</b>		
0-9 years	114	7.09

10-19 years	171	10.64
20-29 years	226	14.06
30-39 years	507	31.55
>=40 years	589	36.65
<b>Enrollment Settings</b>		
Community	197	12.26
Facility	1410	87.74
<b>Clinical Staging</b>		
Stage I	1537	95.64
Stage II	62	3.86
Stage III	8	0.50
<b>TB Co-infection</b>		
No	1557	96.89
Yes	50	3.11
<b>ART Regimen Line</b>		
First line	1506	93.71
Second Line	101	6.29
<b>Duration on ARV</b>		
0-2 years	361	22.46
3-5 years	550	34.23
6-10 years	463	28.81
>10 years	233	14.50
<b>Time to complete EAC sessions</b>		
Median (IQR)	12 (0-9 weeks)	
<= 12 weeks	1516	94.34

13–24 weeks	90	5.60
≥25 weeks	1	0.06
<b>Time from EAC session completion to repeat VL</b>		
Median (IQR)	8 (4-8 weeks)	
<2 weeks	161	10.13
2-4 weeks	140	8.81
4-8 weeks	515	32.39
8-12 weeks	243	15.28
≥12 weeks	531	33.40

197 *DTG-based regimens are the recommended first-line ARV drugs*

198 *Protease inhibitor-based regimens are the recommended second-line ARV drugs*

199

200 **Table 2: Results showing the relationship between baseline characteristics and VL resuppression**

Characteristics	Detectable and suppressed <1000-50 copies/ml N (%)	VL undetectable <50 copies/ml N (%)	Total Suppressed <1000 copies/ml N (%)	Unsuppressed ≥1000 copies/ml N (%)	P value
<b>Total</b>	<b>336</b>	<b>1118</b>	<b>1454</b>	<b>153</b>	
<b>Gender</b>					
Female	219(22.91)	737(77.09)	956 (90.70)	98 (9.30)	0.6742
Male	117(23.49)	381(76.91)	498 (9.05)	55 (9.95)	
<b>Age group</b>					
0-9 years	39(36.79)	67(63.21)	106 (92.98)	8 (7.02)	

10-19 years	32(22.70)	109(77.30)	141 (82.46)	30 (17.54)	<b>&lt;.0031</b>
20-29 years	45(21.63)	163(78.37)	208 (92.04)	18 (7.96)	
30-39 years	98(21.44)	359(78.56)	457 (90.14)	50 (9.86)	
>=40 years	122(22.51)	420(77.49)	542 (92.02)	47 (7.98)	
<b>Enrollment</b>					
<b>Settings</b>					
Community	20(10.70)	167(89.30)	187 (94.92)	10 (5.08)	
Facility	316(24.94)	951(75.06)	1267 (89.86)	143 (10.14)	<b>&lt;.0233</b>
<b>Clinical Staging</b>					
Stage I	324(23.19)	1073(76.81)	1397 (90.89)	140 (9.11)	
Stage II	11(21.15)	41(78.85)	52 (83.87)	10 (16.13)	<b>0.0047</b>
Stage III	1(20.00)	4(80.00)	5 (62.50)	3 (37.50)	
<b>TB Co-infection</b>					
No	332(23.55)	1078(76.45)	1410 (90.56)	147 (9.44)	<b>&lt;.0001</b>
Yes	4(9.09)	40(90.91)	44 (88.00)	6 (12.00)	
<b>ART Regimen Line</b>					
First line	321(22.80)	1087(77.20)	1408 (93.49)	55 (54.46)	<b>&lt;.0001</b>
Second Line	15(32.61)	31(67.39)	46 (45.54)	98 (6.51)	
<b>Duration on ARV</b>					
0-2 years	66(19.64)	270(80.36)	336 (93.07)	25 (6.93)	
3-5 years	102(20.32)	400(79.68)	502 (91.27)	48 (8.73)	<b>&lt;.0259</b>
6-10 years	115(27.64)	301(72.36)	416 (89.85)	47 (10.15)	
>10 years	53(26.50)	147(73.50)	200 (85.84)	33 (14.16)	

201

202 Factors Associated with VL Re-suppression.

203 In the unadjusted model analysis, only age, enrollment setting, ART regimen line, and ART duration  
204 were significantly associated with VL re-suppression (Table 3). ROC in the 10-19 years age band were  
205 13% more likely to be re-suppressed compared to the 0-9 years (CRR: 1.13; 95% CI 1.04 to 1.23).  
206 Similarly, ROC in the 20 -29 years (CRR: 1.02; 95% CI 0.96 to 1.08), 30-39 years (CRR: 1.04; 95% CI 0.98  
207 to 1.11) and  $\geq 40$  years (CRR: 1.11; 95% CI 0.96 to 1.07) age bands were more likely to be re-  
208 suppressed; however, these were not statistically significant. ROC enrolled in the facility were 5.6%  
209 more likely to be resuppressed post-EAC than those enrolled in community settings (CRR: 1.06; 95% CI  
210 1.02 to 1.10). Conversely, ROC on second-line ART regimens were 49% less likely to be re-suppressed  
211 when compared to ROC who were on first-line ART regimens at the time of analysis (CRR: 0.49; 95% CI  
212 0.39 to 0.60). Our analysis found that the likelihood of re-suppression post-EAC increased with a longer  
213 time on treatment: 3-5 years (CRR: 1.02; 95% CI 0.98 to 1.60); 6-10 years (CRR: 1.04; 95% CI 0.99 to  
214 1.08); and  $>10$  years (CRR: 1.08; 95% CI 1.02 to 1.15) respectively. ROC who had been on ART treatment  
215 for more than 10 years had a statistically significant 8% higher likelihood of re-suppression than ROC  
216 who had been on ART treatment for no more than 2 years.

217

218 Our adjusted model found age group and ART regimen line as the two factors significantly associated  
219 with viral re-suppression (Table 3). ROC in the 10-19 years age band were 10% more likely to be re-  
220 suppressed compared to the 0-9 years (ARR: 1.10; 95% CI 1.01 to 1.19), which was slightly lower than  
221 the probability from our bivariate analysis. While all other age bands had a reduced likelihood of re-  
222 suppression, this was not statistically significant. Notably, there was a 50% reduced likelihood of viral  
223 re-suppression among ROC on second-line regimens compared to ROC on first-line regimens (ARR:  
224 0.50; 95% CI 0.41 to 0.62).

225

226

227 Table 3. Demographic and clinical characteristics associated with resuppression of VL after completion  
228 of enhanced adherence counseling

Characteristics	CRR (95% CI)	ARR (95% CI)	P value
<b>Total</b>			
<b>Gender</b>			
Female	reference	reference	
Male	1.0072 (0.9737 - 1.0418)	1.0031 (0.9716-1.0357)	0.8472
<b>Age group</b>			
0-9 years	reference	reference	
10-19 years	1.1305 (1.0378 -1.2313) *	1.0958 (1.0101-1.1886)	<b>0.0276</b>
20-29 years	1.0174 (0.9553 - 1.0836)	0.9969 (0.9361-1.0617)	0.9231
30-39 years	1.0431 (0.9836- 1.1063)	0.9948 (0.941-1.0518)	0.8556
>=40 years	1.1061 (0.9608-1.0746)	0.9774 (0.9264-1.0312)	0.4024
<b>Enrollment</b>			
<b>Settings</b>			
Community	reference	reference	
Facility	1.0564 (1.0183 -1.0959) *	1.0088 (0.9725-1.0465)	0.6390
<b>Clinical Staging</b>			
Stage I	reference	reference	
Stage II	1.0837 (0.9705 -1.2101)	1.0759 (0.9687 -1.195)	0.1717
Stage III	1.4543 (0.8500 -2.4880)	1.2497 (0.7671 -2.0361)	0.3707
<b>TB Co-infection</b>			
No	reference	reference	
Yes	1.0291 (0.9278 -1.1414)	1.0353 (0.9469 -1.1319)	0.4461

---



---

### ART Regimen Line

First line	reference	reference	
Second Line	0.4871 (0.3934 -0.6032) *	0.5043 (0.4082 -0.6229)	<b>&lt;.0001</b>

---



---

### Duration on ARV

0-2 years	reference	reference	
3-5 years	1.0197 (0.9815 -1.0595)	0.9953 (0.959 -1.033)	0.8039
6-10 years	1.0359 (0.9937- 1.0799)	0.9962 (0.9561 -1.0381)	0.8572
>10 years	1.0843 (1.0219 -1.1505) *	1.0017 (0.9461 -1.0605)	0.9543

229 CRR =crude risk ratio; ARR=adjusted risk ratio \* = p < 0.05

230

## 231 Discussion

232 Our study explored the factors associated with VL re-suppression among 1,607 ROCs who completed  
 233 EAC in RISE-supported facilities across five states in Nigeria. After completing EAC, 91% of participants  
 234 achieved a suppressed VL post-EAC, with 23% having VL between  $\geq 50$  and  $< 1000$  copies/ml and 76%  
 235 having an undetectable VL. Factors associated with VL re-suppression were age and ART regimen line.  
 236 Our rate of re-suppression is similar to results from other studies that showed rates of re-suppression  
 237 of 90% -95% after EAC [9,13,18]. Re-suppression rates depend on EAC's type, intensity, and  
 238 documentation [13,19]. Compared to findings from other similar studies, our 91% re-suppression rate  
 239 was the highest.

240

241 The demographic and clinical characteristics of the ROC in this study provided further insights into the  
 242 factors associated with VL re-suppression. Age was found to be associated with VL re-suppression, with  
 243 ROC aged 10-19 years significantly more likely to be re-suppressed post-EAC. This finding suggests that  
 244 this age band may be associated with better post-EAC adherence and treatment outcomes. Our results

245 may be explained by the immediate enrollment on Operation Triple Zero (OTZ), intensive follow-up of  
246 such children and adolescents, and caregiver involvement in care by the RISE team. Unlike our findings  
247 around age, other studies have found that adolescents were less likely to be re-suppressed post-EAC  
248 [9,24]. Similarly, previous studies have found that children and adolescents had comparatively lower  
249 suppression rates, with a higher probability of viral suppression among older adolescents [25,26].  
250 Alongside poor adherence, this noted sub-optimal suppression among children and adolescents has  
251 been attributed to challenges around access to health facilities, satisfaction with healthcare services,  
252 and psychosocial factors, including stigma, school-related activities, caregiver status, knowledge, and  
253 availability [27–30].

254

255 The overall proportion of ROC with VL re-suppression did not differ between ROC enrolled in health  
256 facilities compared to those in the community. Community ART service delivery has been noted to  
257 improve ART uptake, retention, and viral suppression [31–33]. However, a study assessing facility and  
258 community refill strategies after community enrollment has noted no difference in viral suppression  
259 [34]. Moreover, the provision of comprehensive HIV care services in community settings where ROC  
260 may have relatively better access to counseling, support, and regular monitoring is effective in  
261 increasing HIV treatment coverage, and an optimal combination of both community and facility  
262 approaches will be vital in improving treatment outcomes [35].

263

264 Similar to the enrollment settings above, ROC who had been on ART for over 10 years were significantly  
265 more likely to be re-suppressed from our bivariate analysis but not in our multivariate analysis. VL  
266 suppression has been generally associated with increasing duration on treatment and adherence  
267 [26,36–38]. However, a study conducted in Ethiopia on VL among ROC post-EAC noted that ROCs on  
268 ART treatment between 3-5 years were less likely to be re-suppressed, unlike ours [18].



269

270 ART regimen was a significant predictor in our bivariate and multivariate analyses. ROC on second-line  
271 ART regimens were less likely to be resuppressed. This could be due to the majority 1,376 (91%) of ROC  
272 being on DTG-based first-line regimens per the Nigeria National Treatment Guidelines [39]. DTG-based  
273 regimens have been proven to be highly efficacious in achieving virological suppression in ROC  
274 [38,40,41]. In addition, the prior viral unsuppressed results may have been due to non-adherence, and  
275 with improved adherence following the EAC sessions, we would expect comparatively better viral re-  
276 suppression.

277

278 Furthermore, with the introduction and transition of ROC to DTG-based regimens, ROC who had been  
279 on second-line regimens may have never benefitted from the new DTG-based regimens or may have  
280 been transitioned back to the new DTG-based regimens. However, two studies on virological outcomes  
281 post-EAC in Nigeria and Zimbabwe have noted a higher likelihood of viral re-suppression among ROC  
282 on second-line ART regimens [2,21]. This has been attributed to possible lower resistance to second-  
283 line drugs and ROC's "last chance" perception of medically responsive therapy [21]. Moreover,  
284 unsuppressed VL post-EAC has been associated with prolonged first-line ART regimen treatment and  
285 drug resistance [13].

286

287 The strength of this study is the use of routine program data, which provides valuable insights into the  
288 real-world effectiveness of EAC in Nigeria. However, there are several limitations to consider. First, the  
289 data used was cross-sectional, so causality cannot be inferred from the findings. Second, the analysis  
290 relied on routine program data, which may be subject to missing or incomplete information.  
291 Additionally, the analysis was limited to only those variables that are routinely collected from patients  
292 during visits and available in the EMR. We did not measure other potential vital factors that may be

293 associated with VL re-suppression, such as socioeconomic factors, social support, or mental health  
294 status.

295

296 In conclusion, this study highlights the effectiveness of EAC in promoting VL suppression in routine  
297 program settings, with 91% re-suppression. The findings suggest that EAC can improve adherence to  
298 antiretroviral therapy and achieve the UNAIDS global target of 95% VL suppression. The study also  
299 identified essential factors associated with VL re-suppression, including age and ART regimen type.  
300 These findings have implications for programmatic and clinical decision-making and highlight the need  
301 for tailored interventions.

302 **Acknowledgments.**

303

## 304 **References**

- 305 1. World Health Organization. The use of antiretroviral drugs for treating and preventing hiv  
306 infection. 2016.
- 307 2. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al. Enhanced  
308 adherence counselling and viral load suppression in HIV seropositive patients with an initial  
309 high viral load in Harare, Zimbabwe: Operational issues. PLoS ONE. 2019 Feb;14(2).
- 310 3. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Understanding Fast-Track:  
311 Accelerating action to end the AIDS epidemic by 2030. 2015.
- 312 4. World Health Organization. GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND  
313 ON PRE-EXPOSURE PROPHYLAXIS FOR HIV. 2015.

- 314 5. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors  
315 Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral  
316 Therapy in Uganda, August 2014-July 2015. BMC Infectious Diseases. 2017 May;17(1).
- 317 6. Yiltok E, Agada C, Zoakah R, Malau A, Tanyishi D, Ejeliogu E, et al. Clinical profile and viral load  
318 suppression among HIV positive adolescents attending a tertiary hospital in North Central  
319 Nigeria. Journal of Medicine in the Tropics. 2020;22(2):133.
- 320 7. Bonner K, Mezocho A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce  
321 adherence: A systematic review. Journal of Acquired Immune Deficiency Syndromes. 2013  
322 Sep;64(1):74–8.
- 323 8. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient Retention and  
324 Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A  
325 Longitudinal Analysis for Risk Factors. Myer L, editor. PLoS ONE. 2010 May;5(5):e10584.
- 326 9. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated  
327 with virological failure and suppression after enhanced adherence counselling, in children,  
328 adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS ONE. 2015  
329 Feb;10(2).
- 330 10. Labhardt ND, Bader J, Lejone TI, Ringera I, Hobbins MA, Fritz C, et al. Should viral load  
331 thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on  
332 antiretroviral therapy in resource-limited settings. Medicine. 2016 Jul;95(28):e3985.
- 333 11. WHO. world health Organisation. 2016. The Use of Antiretroviral Drugs for treating And  
334 Preventing HIV infection guidelines HIV/AIDS Programme.
- 335 12. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Jouquet G, et al. Impact and  
336 programmatic implications of routine viral load monitoring in swaziland. Journal of Acquired  
337 Immune Deficiency Syndromes. 2014 Sep;67(1):45–51.

- 338 13. Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated  
339 viral load: a systematic review and meta-analysis. *Journal of the International AIDS Society*.  
340 2019 Nov;22(11).
- 341 14. National Agency for the Control of AIDS (NACA). NATIONAL HIV AND AIDS STRATEGIC  
342 FRAMEWORK 2021-2025. 2022.
- 343 15. Federal Ministry of Health N. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018:  
344 Technical Report. Abuja; 2019.
- 345 16. Monitoring GA. Country progress report - Nigeria. 2020;
- 346 17. Negedu-Momoh OR, Balogun O, Dafa I, Etuk A, Oladele EA, Adedokun O, et al. Estimating HIV  
347 incidence in the Akwa Ibom AIDS indicator survey (AKAIS), Nigeria using the limiting antigen  
348 avidity recency assay. *Journal of the International AIDS Society*. 2021 Feb;24(2):e25669.
- 349 18. Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced  
350 Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in  
351 North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. *AIDS*  
352 *research and treatment*. 2020;2020:8909232.
- 353 19. Etoori D, Ciglenecki I, Ndlangamandla M, Edwards CG, Jobanputra K, Pasipamire M, et al.  
354 Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy  
355 adherence and rationalize second-line switches in Swaziland. *Journal of the International AIDS*  
356 *Society*. 2018 Oct;21(10):e25194.
- 357 20. Ali MW, Musa MS. The effect of mobile phone utilization for enhanced adherence counselling  
358 intervention among persons with HIV. *AIDS Care*. 2023 Feb 13;1–9.
- 359 21. Awolude OA, Olaniyi O, Moradeyo M, Abiolu J. Virologic Outcomes Following Enhanced  
360 Adherence Counselling among Treatment Experienced HIV Positive Patients at University

- 361 College Hospital, Ibadan, Nigeria. *International STD Research & Reviews*. 2021 Mar 2;10(1 SE-  
362 Original Research Article):53–65.
- 363 22. Laxmeshwar C, Acharya S, Das M, Keskar P, Pazare A, Ingole N, et al. Routine viral load  
364 monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India.  
365 *PLOS ONE*. 2020 May 5;15(5):e0232576.
- 366 23. Ukwueze LN, Ifeanyi C, Iroegbu A, Aribike J, Ikeneche NF. Evaluation of  
367 Enhanced Adherence Counselling among Virally Unsuppressed HIV-Infected Adults on  
368 Antiretroviral Therapy in Suburban and Metropolitan parts of Delta State , Nigeria. 2021;5(04).
- 369 24. Mhlanga TT, Jacobs BKM, Decroo T, Govere E, Bara H, Chonzi P, et al. Virological outcomes and  
370 risk factors for non-suppression for routine and repeat viral load testing after enhanced  
371 adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional  
372 study using laboratory data from 2014 to 2018. *AIDS Research and Therapy*. 2022;19(1):34.
- 373 25. Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral  
374 suppression rates following the intensive adherence counseling (IAC) program for children and  
375 adolescents with viral failure in public health facilities in Uganda. *BMC Public Health*.  
376 2018;18(1):1048.
- 377 26. Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors associated with viral non-  
378 suppression among adolescents living with HIV in Cambodia: a cross-sectional study. *AIDS*  
379 *research and therapy*. 2018 Nov;15(1):20.
- 380 27. Montalto GJ, Sawe FK, Miruka A, Maswai J, Kiptoo I, Aoko A, et al. Diagnosis disclosure to  
381 adolescents living with HIV in rural Kenya improves antiretroviral therapy adherence and  
382 immunologic outcomes: A retrospective cohort study. *PLOS ONE*. 2017 Oct  
383 9;12(10):e0183180.

- 384 28. Eticha T, Berhane L. Caregiver-reported adherence to antiretroviral therapy among HIV  
385 infected children in Mekelle, Ethiopia. *BMC Pediatrics*. 2014;14(1):114.
- 386 29. Bikaako-Kajura W, Luyirika E, Purcell DW, Downing J, Kaharuza F, Mermin J, et al. Disclosure of  
387 HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. *AIDS*  
388 and behavior. 2006 Jul;10(4 Suppl):S85-93.
- 389 30. Gichane MW, Sullivan KA, Shayo AM, Mmbaga BT, O' Donnell K, Cunningham CK, et al.  
390 Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. *AIDS*  
391 care. 2018 Jun;30(6):701–5.
- 392 31. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of Offering  
393 Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to  
394 Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized  
395 Clinical Trial. *JAMA*. 2018 Mar;319(11):1103–12.
- 396 32. Eshun-Wilson I, Awotiwon AA, Germann A, Amankwaa SA, Ford N, Schwartz S, et al. Effects of  
397 community-based antiretroviral therapy initiation models on HIV treatment outcomes: A  
398 systematic review and meta-analysis. *PLOS Medicine*. 2021 May 28;18(5):e1003646.
- 399 33. Barnabas R V, Szpiro AA, van Rooyen H, Asimwe S, Pillay D, Ware NC, et al. Community-based  
400 antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda  
401 (DO ART): a randomised trial. *The Lancet Global health*. 2020 Oct;8(10):e1305–15.
- 402 34. Amstutz A, Lejone TI, Khesa L, Kopo M, Kao M, Bresser M, et al. Offering ART Refill Through  
403 Community Health Workers Versus Clinic-Based Follow-Up After Home-Based Same-Day ART  
404 Initiation: The VIBRA Cluster-Randomised Clinical Trial. 2021;
- 405 35. Oladele EA, Badejo OA, Obanubi C, Okechukwu EF, James E, Ow'honda G, et al. Bridging the HIV  
406 treatment gap in Nigeria : examining community antiretroviral treatment models. 2018;

- 407 36. Tomescu S, Crompton T, Adebayo J, Akpan F, Dauda DS, Allen Z, et al. Factors associated with  
408 viral load non-suppression in people living with HIV on ART in Nigeria: cross-sectional analysis  
409 from 2017 to 2021. *BMJ open*. 2023 May;13(5):e065950.
- 410 37. van Liere GAFS, Lilian R, Dunlop J, Tait C, Rees K, Mabitsi M, et al. High rate of loss to follow-up  
411 and virological non-suppression in HIV-infected children on antiretroviral therapy highlights  
412 the need to improve quality of care in South Africa. *Epidemiology and infection*. 2021  
413 Mar;149:e88.
- 414 38. Mehari EA, Muche EA, Gonete KA. Virological Suppression and Its Associated Factors of  
415 Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective  
416 Study in Ethiopia. *HIV/AIDS (Auckland, NZ)*. 2021;13:709–17.
- 417 39. Federal Ministry of Health Nigeria. National Guidelines for HIV Prevention, Treatment and  
418 Care. 2020.
- 419 40. Abudiore O, Amamilo I, Campbell J, Eigege W, Harwell J, Conroy J, et al. High acceptability and  
420 viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter  
421 study in Nigeria. *PLOS ONE*. 2023 May 17;18(5):e0284767.
- 422 41. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High acceptability  
423 and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in  
424 Uganda: A mixed-methods prospective cohort study. *PLOS ONE*. 2020 May 27;15(5):e0232419.  
425  
426